Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP260159.RAc9kyd5HH0vU2XxgkV5MJDlUFORvvqMu_VzMPBz2Ygas130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP260159.RAc9kyd5HH0vU2XxgkV5MJDlUFORvvqMu_VzMPBz2Ygas130_assertion type Assertion NP260159.RAc9kyd5HH0vU2XxgkV5MJDlUFORvvqMu_VzMPBz2Ygas130_head.
- NP260159.RAc9kyd5HH0vU2XxgkV5MJDlUFORvvqMu_VzMPBz2Ygas130_assertion description "[Forty-eight-hour treatment of colon cancer HCT-116 and HT-29 cells with FOLFOX resulted in 60-70% survival, accompanied by a marked activation of insulin like growth factor-1 receptor (IGF-1R) and minor to moderate increase in epidermal growth factor receptor (EGFR), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (HER-2) as well as v-akt murine thymoma viral oncogene homolog 1 (AKT), cyclooxygenase-2 (COX-2) and cyclin-D1.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP260159.RAc9kyd5HH0vU2XxgkV5MJDlUFORvvqMu_VzMPBz2Ygas130_provenance.
- NP260159.RAc9kyd5HH0vU2XxgkV5MJDlUFORvvqMu_VzMPBz2Ygas130_assertion evidence source_evidence_literature NP260159.RAc9kyd5HH0vU2XxgkV5MJDlUFORvvqMu_VzMPBz2Ygas130_provenance.
- NP260159.RAc9kyd5HH0vU2XxgkV5MJDlUFORvvqMu_VzMPBz2Ygas130_assertion SIO_000772 20332435 NP260159.RAc9kyd5HH0vU2XxgkV5MJDlUFORvvqMu_VzMPBz2Ygas130_provenance.
- NP260159.RAc9kyd5HH0vU2XxgkV5MJDlUFORvvqMu_VzMPBz2Ygas130_assertion wasDerivedFrom befree-20150227 NP260159.RAc9kyd5HH0vU2XxgkV5MJDlUFORvvqMu_VzMPBz2Ygas130_provenance.
- NP260159.RAc9kyd5HH0vU2XxgkV5MJDlUFORvvqMu_VzMPBz2Ygas130_assertion wasGeneratedBy ECO_0000203 NP260159.RAc9kyd5HH0vU2XxgkV5MJDlUFORvvqMu_VzMPBz2Ygas130_provenance.